Efficacy and safety benefits of <scp>iGlarLixi</scp> versus insulin glargine 100 U/ <scp>mL</scp> or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The <scp>LixiLan‐O‐AP</scp> randomized controlled trial

Abstract

iGlarLixi achieved significant HbA1c reductions, to near-normoglycaemic levels, compared with iGlar or Lixi, with no meaningful additional risk of hypoglycaemia and mitigated body weight gain versus iGlar, with fewer gastrointestinal adverse events versus Lixi. iGlarLixi with specifically adapted ratios may provide an efficacious and well-tolerated treatment option for Asian Pacific people with T2D.